RxDoctor Payments Data

David Weiner, MD

Urology · New York, NYNPI 1013941673

Payments from drug & device makers

$4,105in general payments, 2019–2025

Across 132 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$710
  • Teleflex LLC$607
  • Antares Pharma, Inc.$514
  • Sumitomo Pharma America, Inc.$500
  • Boston Scientific$358
  • Urovant Sciences Inc$289
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,105 in reported general payments places this provider in the 55th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$290,494
Medicare patients
985
Services billed
2,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron180$179,384
MyrbetriqMirabegron167$159,239
OrgovyxRelugolix11$29,826
Mirabegron ErMirabegron24$19,375
Silodosin88$11,247
Tamsulosin Hcl586$9,984
AndrogelTestosterone12$7,802
Finasteride322$5,252
Potassium Citrate ErPotassium Citrate31$4,947
Dutasteride126$4,555
Alfuzosin Hcl ErAlfuzosin Hcl156$4,014
Tadalafil38$3,014
Methenamine Hippurate22$1,676
Testosterone23$1,540
Cefpodoxime Proxetil44$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$500$209,209191 claims
Astellas Pharma US IncMyrbetriq$710$159,239167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →